Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients.
Anti-inflammatory substances are released during septic shock that modulate monocyte function. Decreased monocyte responsiveness to bacterial toxins and decreased expression of human-leukocyte-associated antigen-DR (HLA-DR) have been reported during septic shock and critical illness. Impaired antigen presentation has been inferred from these observations but has not been demonstrated. We assessed antigen presentation and costimulatory molecule expression in 12 age-matched control subjects, 10 noninfected critically ill patients (CINS), and 17 critically ill patients with sepsis (CIS). Antigen presentation was assessed by using in vitro lymphocyte 5-bromo-2-deoxyuridine (BrdU) incorporation in response to tetanus toxoid. The expression of HLA-DR and the costimulatory molecules CD28, CD86, and CTLA-4 was assessed by flow cytometry. Serum interleukin-10 (IL-10) was also measured by enzyme-linked immunosorbent assay. Serum IL-10 levels were significantly elevated in CIS patients (91 +/- 38 pg/mL) as compared with levels in control subjects (5 +/- 4 pg/mL)(P < .05). Lymphocyte BrdU incorporation increased by 710% +/- 243% in control subjects but by only 144% +/- 62% in CIS patients and 76% +/- 31% in CINS patients (P < .01 vs control). Monocyte HLA-DR expression, monocyte CD86 expression, and lymphocyte CD28 expression were significantly decreased in CIS patients (P < .01) as compared with control subjects. Conversely, lymphocyte CTLA-4 expression was significantly increased in CIS patients (P < .05 vs control). Monocyte CD86 expression was also significantly decreased in CINS patients as compared with control subjects. These data indicate that antigen presentation is decreased in critically ill patients with sepsis. This appears in part related to decreased expression of HLA-DR and the costimulatory molecules CD86 and CD28. Increased expression of the negative signal receptor CTLA-4 may also impair antigen presentation in patients with sepsis.
Manjuck
J
J
Saint Vincents Hospital and Medical Center, New York Medical College, NY 10011, USA.
Saha
D C
DC
Astiz
M
M
Eales
L J
LJ
Rackow
E C
EC
D000069594:Abatacept; D015703:Antigens, CD / Q000097:blood; D000943:Antigens, Differentiation / Q000097:blood; D051940:B7-2 Antigen; D001427:Bacterial Toxins / Q000276:immunology*; D018106:CD28 Antigens / Q000097:blood; D060908:CTLA-4 Antigen; D002478:Cells, Cultured; D016638:Critical Illness; D005260:Female; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D018796:Immunoconjugates; D016753:Interleukin-10 / Q000097:blood; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D012016:Reference Values; D012772:Shock, Septic / Q000097:blood / Q000276:immunology*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D051940:B7-2 Antigen; D001427:Bacterial Toxins; D018106:CD28 Antigens; C497964:CD86 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D006684:HLA-DR Antigens; D018796:Immunoconjugates; D008562:Membrane Glycoproteins; D016753:Interleukin-10; D000069594:Abatacept